ALK is a global leader in the manufacture of allergen immunotherapy (AIT) products for the causal treatment of allergies. AIT is the only therapy recognized as a causal treatment of allergies by the WHO.
ALK has repeatedly led the industry with pioneering work, e.g. with the launch of the first approved tablet-based AIT to treat grass pollen allergy. In 2015, ALK introduced the first approved tablet to treat house dust mite allergy to the market.
Over the last twenty years, worldwide approximately 1,800,000 patients benefited from the results of the company’s research and development efforts in prevention, diagnosis and therapy of allergies.
Causal treatment with ALK products is indicated in patients with allergic rhinitis and conjunctivitis, allergic bronchial asthma and allergic reactions to bee and wasp stings. In addition, ALK manufactures a special product for the emergency treatment of anaphylactic reactions. With subcutaneous and sublingual formulations as well as tablets, ALK’s range of allergen products offers patients maximum convenience, improving patient adherence to therapy. As the only company offering a broad portfolio of therapies and diagnostic products for the entire family, ALK provides physicians and patients with care from one source. The products containing native allergens consistently comply with the highest quality standards. Due to the partnership with Merck (USA), production at the parent company ALK-Abelló A/S in Denmark is subject to the strict requirements of the US Food and Drug Administration (FDA), in addition to the requirements of the European Medicines Agency (EMA).
ALK is committed to improving the quality of life of people living with allergies. To achieve this aim, ALK invests annually an exceptionally high proportion (about 20%) of its earnings in research and development. ALK has received multiple awards for innovations in the product development of immunotherapies and patient-friendly formulations.